{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:44:51Z","timestamp":1760622291902},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1364,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1998,4]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>It has been suggested that adenosine is involved in the renal haemodynamic and tubular abnormalities observed in cirrhosis. Low\u2010dose theophylline is an adenosine antagonist and recent studies have shown that this drug can improve renal blood flow and sodium excretion in cirrhotic patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Fifteen patients with newly diagnosed cirrhotic ascites were randomized to receive either 100\u2003mg spironolactone daily for 7\u2003days or 250\u2003mg theophylline on days 1, 2, 4 and 6. Baseline clinical and urinary and serum biochemical data were collected and compared following therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>After 7\u2003days of spironolactone there were increases in urinary sodium excretion (43.5\u2003\u00b1\u200315.6 vs. 106.8\u2003\u00b1\u200334.7\u2003mmol\/day; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) and urine volume (769.1\u2003\u00b1\u2003206.5 vs. 1541.6\u2003\u00b1\u2003342.6\u2003mL\/day; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). No changes in the patients\u2019 weight, creatinine clearance or serum electrolytes were observed. No change was detected in any of these parameters following theophylline therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Adenosine antagonism in the form of low\u2010dose theophylline is less efficacious than spironolactone in the management of cirrhotic ascites.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1998.00318.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:36:26Z","timestamp":1047353786000},"page":"389-393","source":"Crossref","is-referenced-by-count":6,"title":["Comparison between theophylline and spironolactone in the management of cirrhotic ascites: a randomized controlled study"],"prefix":"10.1111","volume":"12","author":[{"family":"Stanley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Dabos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840200537"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-8278(21)80003-3","article-title":"Cirrhosis: Ascites and hepatorenal syndrome. Recent advances in pathogenesis","volume":"23","author":"Henriksen JH.","year":"1995","journal-title":"J Hepatol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1983.tb00100.x"},{"key":"e_1_2_5_5_2","first-page":"714","article-title":"Renal function abnormalities in cirrhosis","volume":"3","author":"Arroyo V","year":"1991","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0953-0673.1996.00219.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00607083"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","unstructured":"FredholmBB.Are methylxanthine\u2019s effects due to antagonism of endogenous adenosine?Trends Pharmacol Sci1980; 129\u201332.","DOI":"10.1016\/0165-6147(79)90046-4"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.1.139"},{"key":"e_1_2_5_10_2","first-page":"802","article-title":"Disparate effects of adenosine A1 and A2 receptor agonists on intrarenal blood flow","volume":"265","author":"Agmon Y","year":"1993","journal-title":"Am J Physiol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","unstructured":"StilesG L.Adenosine receptors. J Biol Chem1992;267:64514.","DOI":"10.1016\/S0021-9258(19)50445-8"},{"key":"e_1_2_5_12_2","first-page":"549","article-title":"Mechanism and role of intrinsic regulation of hepatic blood flow\u2014hepatic artery buffer response","volume":"249","author":"Lautt WW.","year":"1985","journal-title":"Am J Physiol"},{"key":"e_1_2_5_13_2","first-page":"838","article-title":"Caffeine withdrawal: apparent heterologous sensitization to adenosine and prostacyclin actions in human platelets","volume":"267","author":"Paul S","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100614"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/hep.510230222","article-title":"Adenosine does not mediate renal sodium retention and peripheral vasodilatation elicited by partial portal vein ligation in rats","volume":"23","author":"Murakami S","journal-title":"Hepatology"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5732.401"},{"key":"e_1_2_5_17_2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0016-5085(83)90198-1","article-title":"Randomized comparative study of efficacy of furosemide vs. spironolactone in nonazotemic cirrhosis with ascites","volume":"84","author":"Perez\u2010Ayuso RM","year":"1983","journal-title":"Gastroenterology"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","unstructured":"ArroyoV GinesP GerbesAL et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.Hepatology1996; 164\u201376.","DOI":"10.1053\/jhep.1996.v23.ajhep0230164"},{"key":"e_1_2_5_19_2","article-title":"Investigation into the effects of FK 352 (a novel adenosine\u20101 antagonist) in cirrhotic patients with ascites: a pilot study","volume":"39","author":"Stanley AJ","year":"1996","journal-title":"Gut"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199305000-00020"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00318.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00318.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1998.00318.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T01:54:40Z","timestamp":1698458080000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1998.00318.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,4]]}},"alternative-id":["10.1046\/j.1365-2036.1998.00318.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1998.00318.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,4]]}}}